News

In an interview with Targeted Oncology, Guenther Koehne, MD, provides a comprehensive overview of the dynamic landscape and evolving strategies in immunotherapy for hematologic malignancies.

Neeraj Agarwal, MD, highlights several exciting prostate cancer developments being presented at the upcoming 2024 Genitourinary Cancers Symposium.

The phase 3 EVOKE-01 trial of sacituzumab govitecan in non–small cell lung cancer missed its primary end point, showing a numerical but not significant improvement in overall survival.

Findings from the phase 2 CAPTIVATE study demonstrate that the doublet of ibrutinib and venetoclax may be an attractive line of therapy for patients with chronic lymphocytic leukemia.

NK010 represents a promising advancement in the landscape of natural killer cell-based immunotherapy across a variety of cancer types.

PTX-252, a novel molecular drug, has received an FDA orphan drug designation for the treatment of patients with acute myeloid leukemia.

In an interview with Targeted Oncology, Louise Morrell, MD, discussed the landscape of genetic testing in oncology and the latest advancements in the field.

Circulating tumor DNA failed to indicate if patients with low-risk stage II colon cancer would benefit from adjuvant chemotherapy after surgery.

The neoadjuvant administration of botensilimab/balstilimab resulted in strong responses in individuals with both resectable mismatch repair–proficient and –deficient colorectal cancer.

In the DeFianCe trial, the combination of DKN-01 with bevacizumab and chemotherapy is being investigated to assess the potential clinical benefits for patients diagnosed with microsatellite stable colorectal adenocarcinoma.

Results from the phase 3 FRESCO-2 trial substantiate the potential of fruquintinib to offer enhanced survival benefits and improved quality of life for individuals with metastatic colorectal cancer who have undergone prior treatments.

Results from the phase 3 CheckMate-8HW trial support first-line treatment with nivolumab plus ipilimumab as a standard-of-care option for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.

Clinical characteristics were associated with long-term remission to regorafenib in patients with metastatic colorectal cancer.

Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.

The updated data of larotrectinib as a treatment in TRK fusion GI cancers continued to demonstrate optimal responses, survival, and safety.

From 2013 to 2022, the use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer, with a trend in patients aged 50 years and younger.

Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.

Riccardo Lencioni, MD, discusses how the new protocol from the phase 3 EMERALD-1 trial may be implemented in the community oncology setting for the treatment of hepatocellular carcinoma.

Fostroxacitabine bralpamide combined with lenvatinib showed acceptable safety and tolerability, while inducing promising efficacy in patients with hepatocellular carcinoma.

Neoadjuvant camrelizumab in combination with nab-paclitaxel and cisplatin exhibited enhanced pathological complete response compared to solitary chemotherapy in individuals diagnosed with esophageal squamous cell carcinoma.

The frontline use of pembrolizumab plus lenvatinib in patients with advanced HCC showed a 3-year or more response among 35% of responders; however, additional efficacy results remained consistent with previous findings from the phase 3 LEAP-002 trial.

Marcia S. Brose, MD, PhD, FASCO, discusses her hopes for the future of selpercatinib in treating advanced or metastatic RET-mutant thyroid cancer.

The FDA has approved erdafitinib for the treatment of locally advanced or metastatic urothelial carcinoma with FGFR3 alterations.

The combination of neoadjuvant FLOT with durvalumab demonstrated enhanced pathological complete response compared to sole chemotherapy in individuals with resectable gastric and GEJ cancers, regardless of geographical location.

An immunotherapy combination with chemotherapy significantly extended survival and delayed cancer progression in patients with esophageal squamous cell carcinoma compared with standard chemotherapy alone.

A study has identified a genetic mechanism, DHX9, making small cell lung cancer responsive to immunotherapy. This is a pivotal breakthrough for treatment of a historically resistant disease.

In an interview with Targeted Oncology, Amer Assal, MD, provided insights into the risks and complications associated with stem cell transplants, emphasizing the importance of risk stratification and preventive measures.